首页> 美国卫生研究院文献>Scientific Reports >Multiple-factor analysis of the first radioactive iodine therapy in post-operative patients with differentiated thyroid cancer for achieving a disease-free status
【2h】

Multiple-factor analysis of the first radioactive iodine therapy in post-operative patients with differentiated thyroid cancer for achieving a disease-free status

机译:分化型甲状腺癌术后患者达到无病状态的首次放射性碘治疗的多因素分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

131I treatment is an important management method for patients with differentiated thyroid cancer (DTC). Unsuccessful 131I ablation drastically affects the prognosis of the patients. This study aimed to analyze potential predictive factors influencing the achievement of a disease-free status following the first 131I therapy. This retrospective review included 315 DTC patients, and multiple factors were analyzed. Tumor size, pathological tumor stage, lymph node (LN) metastasis, distant metastasis, American Thyroid Association recommended risks, pre-ablation thyroglobulin (Tg), and thyroid stimulating hormone (TSH) displayed significant differences between unsuccessful and successful group. Cutoff values of Tg and TSH to predict a successful outcome were 3.525 ng/mL and 99.700 uIU/ml by receiver operating characteristic curves analysis. Binary logistic regression analysis showed that tumor stage T3 or T4, LN metastasis to N1b station, intermediate and high risks, pre-ablation Tg ≥ 3.525 ng/ml and TSH <99.700 μIU/mL were significantly associated with unsuccessful outcomes. Logistic regression equation for achieving a disease-free status could be rendered as: y (successful treatment) = −0.270–0.503 X1 (LN metastasis) −0.236 X2 (Tg) + 0.015 X3 (TSH). This study demonstrated LN metastasis, pre-ablation Tg and TSH were the most powerful predictors for achieving a disease-free status by the first 131I therapy.
机译: 131 I治疗是分化型甲状腺癌(DTC)患者的重要治疗方法。 131 I消融失败会严重影响患者的预后。这项研究旨在分析影响 131 I首次疗法后实现无病状态的潜在预测因素。这项回顾性研究包括315名DTC患者,并分析了多个因素。肿瘤大小,病理肿瘤分期,淋巴结转移(LN),远处转移,美国甲状腺协会推荐的风险,消融前甲状腺球蛋白(Tg)和促甲状腺激素(TSH)在成功与失败组之间显示出显着差异。通过接受者工作特征曲线分析,预测成功结果的Tg和TSH的临界值为3.525μng/ mL和99.700μuIU/ ml。二元逻辑回归分析显示,肿瘤T3或T4期,LN转移至N1b站,中度和高风险,消融前Tg≥3.525mlng / ml和TSH <99.700 IU / mL与未成功结局显着相关。获得无病状态的逻辑回归方程可表示为:y(成功治疗)= -0.270-0.503 X1(LN转移)-0.236 X2(Tg)+ 0.015 X3(TSH)。这项研究表明,LN转移,消融前Tg和TSH是通过 131 I疗法实现无病状态的最有力预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号